← Articles
Read in another language
Lifestyle

The Sleep Economy: When Rest Became a Product

Jayden

Analyzes global supply chains, industrial policy, and technology issues.

Published

Key points

  • RAND Europe's 2016 model estimated that insufficient sleep costs the United States up to $411 billion a year — about 2.28% of GDP — with roughly 1.2 million working days lost annually. These are modelled estimates, not measured invoices.
  • The National Sleep Foundation's 2025 poll found six in ten US adults still fall short of seven to nine hours of quality sleep, and nearly four in ten have trouble falling asleep at least three nights a week.
  • The treatment with the strongest evidence is not a product: the American Academy of Sleep Medicine makes CBT-I its strong, first-line recommendation for chronic insomnia, while sleep hygiene on its own is not an effective standalone treatment.
  • Supplement labels are claims, not guarantees — a 2017 Journal of Clinical Sleep Medicine analysis found melatonin content ranging from 83% below to 478% above the label, with more than 70% of products missing their own label by more than 10%.
  • A wrist score is an estimate and a sleep lab is a measurement: across 11 consumer trackers, sleep-stage agreement ran from poor to moderate, deep sleep was correctly identified around 59% of the time in one cited study, and chasing the number can tip into orthosomnia, whose estimated prevalence ranges from about 3% to 14% depending on the criteria.

For most of human history, sleep was the one thing you could not buy. You lay down, and either it came or it didn't. In 2026 that is no longer quite true. Sleep tourism — booking a trip whose entire purpose is to rest — has been named one of the year's defining travel trends, with hotels and resorts selling blackout suites, circadian lighting and "sleep concierges" [source: Grand View Research, 2025]. At the same time, the National Sleep Foundation's 2025 poll found that six in ten American adults still do not get the recommended seven to nine hours of quality sleep, and nearly four in ten struggle to fall asleep at least three nights a week [source: National Sleep Foundation, 2025]. That is the paradox worth opening with: we are spending more on sleep than ever, and sleeping no better.

This article maps the sleep economy — mattresses and smart beds, wearables and apps, supplements, and sleep-focused travel — and tries to keep three lines sharp throughout. First, the line between validated sleep science and marketing claims. Second, the line between the "estimated" sleep score on your wrist and the "measured" data of a clinical sleep lab. Third, the point at which chasing better sleep starts to make it worse. None of this is medical advice; if sleep problems persist, that is a conversation for a clinician, not a checkout cart.

Table of Contents

  1. Why we started paying to sleep
  2. What the sleep economy actually sells
  3. What works: science versus marketing
  4. Your sleep score versus the sleep lab
  5. When chasing sleep backfires: orthosomnia
  6. What to watch

Why we started paying to sleep

The commercial case for sleep rests on a genuine finding: sleeping badly is expensive. A widely cited RAND Europe analysis estimated that insufficient sleep costs the United States up to US$411 billion a year — about 2.28% of GDP — through lost productivity and higher mortality risk, with the country shedding roughly 1.2 million working days annually [source: RAND Europe, 2016]. The same model suggested that nudging people who sleep under six hours up to six or seven could add about US$226 billion to the US economy [source: RAND Europe, 2016]. Those are modelled estimates, not measured invoices, and the study dates from 2016 — but the direction is hard to argue with, and it reframed sleep from a personal habit into an economic input.

Culture caught up with the accounting. Sleep now sits inside the broader "wellness economy," which the Global Wellness Institute valued at US$6.8 trillion in 2024 and expects to reach US$9.8 trillion by 2029 [source: Global Wellness Institute, 2025]. Within that, sleep is one of the fastest-moving pieces: the Institute reports the sleep sub-segment of mental wellness grew about 12.6% a year between 2019 and 2024 [source: Global Wellness Institute, 2025]. It is worth noting what that figure is not — the Institute does not publish a single clean "sleep market" number, so anyone who quotes one is stitching together sources. Still, the pattern is clear: rest has been repackaged as something you invest in, optimize and, increasingly, purchase.

What the sleep economy actually sells

The sleep economy is really four overlapping markets, and their sizes should be read with caution — most figures come from commercial market-research firms, and they vary enormously depending on how each defines the category.

The oldest pillar is mattresses and smart beds. Estimates for the global mattress market cluster somewhere between US$49 billion and US$58 billion for 2024–2025, growing around 7% a year, though different firms disagree by billions [source: Grand View Research, 2025]. Layered on top is a newer category of "smart" beds and sleep-optimized bedding that promise temperature control and posture sensing.

The second pillar is wearables and apps — the rings, watches and mats that turn a night's sleep into a score. Sleep-tracking hardware is the visible face of the category, and wearables make up the large majority of it, but the crucial point here is not size but function: these devices sell a number, and that number is an estimate, which the next sections take apart.

The third pillar is supplements, led by melatonin. The melatonin supplement market has been valued in the low single-digit billions of dollars, with firms projecting brisk double-digit growth [source: Grand View Research, 2025]. Melatonin is a hormone the body already makes to signal night; taking it can help with circadian problems such as jet lag, but the evidence for it as a general sleeping pill is far thinner than the shelf space suggests.

The fourth and newest pillar is sleep tourism. Hotels accounted for roughly 46% of the sleep-tourism market in 2024, and analysts project low-double-digit annual growth through 2030 [source: Grand View Research, 2025]. The offer ranges from a quiet room with good curtains to medical-grade retreats with sleep assessments and coaching.

Two things are true at once about all of this. Some products genuinely help — a better mattress, a dark room, a consistent wind-down routine are real inputs to real rest. And the category has strong incentives to sell certainty about something inherently uncertain. Holding both ideas together is the whole game.

What works: science versus marketing

Here the layers matter most, because the gap between what sleep scientists endorse and what the market promotes is wide.

Start with the good news that no one is selling, because it is free. The behavioral basics — a regular schedule, a cool dark room, limiting late caffeine and alcohol, and getting out of bed when you cannot sleep — are the substance of "sleep hygiene." But the clinical evidence adds an important asterisk. For chronic insomnia, the American Academy of Sleep Medicine's guideline makes cognitive behavioral therapy for insomnia (CBT-I) its strong, first-line recommendation, while noting that sleep hygiene on its own is not an effective standalone treatment [source: American Academy of Sleep Medicine, 2021]. In other words, the tips the internet gives away for free are helpful habits, but the treatment with the strongest evidence is a structured therapy — not a gadget, a mattress or a tea.

Melatonin is the sharpest example of the science-versus-marketing gap. It can genuinely help reset a body clock knocked off by travel or shift work, but it is not a sedative, and long-term safety data beyond a few months is limited. More troubling is what is actually in the bottle. A 2017 study in the Journal of Clinical Sleep Medicine analyzed commercial melatonin products and found the actual melatonin content ranged from 83% below to 478% above the labelled dose; more than 70% of products missed their own label by more than 10%, and some contained serotonin as a contaminant [source: Journal of Clinical Sleep Medicine, 2017]. Because supplements are lightly regulated, the dose on the label is a claim, not a guarantee — a distinction the packaging rarely makes.

The honest summary is deflating for anyone hoping to buy their way to rest: the interventions with the best evidence are behavioral and clinical, and the products that dominate the market range from genuinely useful to unproven.

Your sleep score versus the sleep lab

Nothing captures the sleep economy better than the morning ritual of checking your "sleep score." It feels like data. It is, more precisely, an estimate — and it is worth understanding how far that estimate can drift from what a clinic would measure.

The clinical gold standard is polysomnography: an overnight lab study that records brain waves, eye movement, muscle activity, breathing and heart rhythm to score sleep stages directly. A consumer wearable has none of that. It infers sleep mostly from movement and heart rate, then models the rest. When researchers put this to the test in a 2023 multicenter study comparing 11 consumer trackers against polysomnography, performance varied widely: agreement scores for classifying sleep stages ranged from poor to moderate across devices, with some showing substantial agreement and others only partial [source: JMIR mHealth and uHealth, 2023]. The characteristic failure is revealing — because the devices lean on movement, they tend to mistake lying still for being asleep, overestimating sleep for exactly the people most worried about it, such as insomniacs who lie awake without moving [source: JMIR mHealth and uHealth, 2023].

The educational arm of the National Sleep Foundation adds two cautions worth repeating: consumer sleep trackers are not regulated by the FDA as medical devices, and even newer models are only moderately good at identifying sleep stages, with one cited study finding trackers correctly identified deep sleep around 59% of the time [source: Sleep Foundation, 2024]. The fair conclusion is not that trackers are useless. For spotting trends over weeks, nudging an earlier bedtime, or raising awareness, they can genuinely help. But a nightly score is a modelled estimate, not a diagnosis — and the two belong in separate columns.

When chasing sleep backfires: orthosomnia

There is a failure mode specific to the quantified approach, and it has a name. In 2017, researchers writing in the Journal of Clinical Sleep Medicine coined "orthosomnia" to describe patients whose pursuit of perfect sleep — driven by their tracker data — was paradoxically making their sleep worse [source: Journal of Clinical Sleep Medicine, 2017]. The anxiety of chasing a better score becomes its own cause of insomnia.

How common is it? The honest answer is that we are still measuring. A 2024 cross-sectional study in Brain Sciences surveyed 523 adults and found that about 36% regularly used sleep trackers; depending on how strictly orthosomnia was defined, its estimated prevalence ranged from about 3% under the most conservative criteria to 14% under the most lenient [source: Brain Sciences, 2024]. Those numbers deserve a caveat the headlines skip: the sample skewed young and heavily female, so it is a signal, not a settled statistic. Reporting elsewhere suggests younger adults are the most susceptible to tracker-induced sleep stress.

This is not an argument against measuring your sleep. For many people, a tracker is a harmless and even motivating tool. It is an argument for holding the number loosely — the moment a device meant to improve your rest becomes a reason to lie awake grading it, the product has begun working against its own promise.

What to watch

The sleep economy is built on something real. Sleeping badly carries genuine costs, a majority of adults fall short of the rest they need, and some of what the market sells — a dark room, a decent mattress, a structured therapy — genuinely helps. But the same evidence counsels a buyer's skepticism. Market sizes are estimates that swing by billions between sources; the score on your wrist is a model, not a measurement; the supplement's label is a claim, not a guarantee; and the strongest treatment for chronic insomnia is a behavioral therapy that no one can package and ship.

A few things are worth watching from here. Will regulators bring supplement labelling and "sleep score" marketing under tighter scrutiny as the category grows? Will wearable accuracy close the gap with clinical measurement, or will the marketing outrun the science? Will sleep tourism mature into evidence-based programs, or settle for luxury with a wellness label? And culturally, will the quantified pursuit of perfect sleep keep feeding the very anxiety that ruins it? The most useful thing a reader can carry away is not a product recommendation but a habit of mind: separate the science from the sale, the estimate from the measurement, and the rest you need from the rest someone is trying to sell you.

Charts

The US economic case for sleep — RAND model estimates

The US economic case for sleep — RAND model estimatesAnnual cost of insufficient sleep (up to) 411USD billion, Potential gain from moving under-6h sleepers to 6–7h 226USD billion411USD billionAnnual cost of insufficient sleep (up to)226USD billionPotential gain from moving under-6h sleepers to 6–7h
RAND Europe (2016). Both figures are modelled estimates rather than measured invoices, and the $411 billion figure is an 'up to' ceiling. The same analysis put the loss at about 2.28% of GDP and roughly 1.2 million working days a year.RAND Europe (opens in a new tab)

The wellness economy sleep sits inside — 2024 value and 2029 forecast

The wellness economy sleep sits inside — 2024 value and 2029 forecast2024 (measured by GWI) 6.8USD trillion, 2029 (forecast) 9.8USD trillion6.8USD trillion2024 (measured by GWI)9.8USD trillion2029 (forecast)
Global Wellness Institute. The 2029 number is a forecast, implying about 7.6% annual growth. The Institute reports the sleep sub-segment of mental wellness grew about 12.6% a year between 2019 and 2024, but publishes no single standalone 'sleep market' figure.Global Wellness Institute (opens in a new tab)

Sleep-stage classification: 11 consumer trackers against polysomnography

Sleep-stage classification: 11 consumer trackers against polysomnographyLowest-scoring device 0.26F1, Highest-scoring device 0.69F10.26F1Lowest-scoring device0.69F1Highest-scoring device
JMIR mHealth and uHealth (2023) multicenter validation study; four-stage macro F1 across devices, ranging from poor to moderate. Because the devices lean on movement, they tend to mistake lying still for sleeping and overestimate sleep.JMIR mHealth and uHealth (opens in a new tab)

Melatonin products: actual content versus the labelled dose

Melatonin products: actual content versus the labelled doseLowest (below label) -83%, Highest (above label) 478%-83%Lowest (below label)478%Highest (above label)
Journal of Clinical Sleep Medicine (Erland & Saxena, 2017). More than 70% of products missed their own label by more than 10%, and some contained serotonin as a contaminant.Journal of Clinical Sleep Medicine (opens in a new tab)

Estimated orthosomnia prevalence, by how strictly it is defined

Estimated orthosomnia prevalence, by how strictly it is definedConservative criteria 3%, Moderate criteria 8.6%, Liberal criteria 14%3%Conservative criteria8.6%Moderate criteria14%Liberal criteria
Brain Sciences (Jahrami et al., 2024), a cross-sectional survey of 523 adults, about 36% of whom used a sleep tracker regularly. The sample skewed young and heavily female, so this is a signal rather than a settled statistic.Brain Sciences (opens in a new tab)

Timeline

  1. RAND Europe publishes Why Sleep Matters, estimating that insufficient sleep costs the US up to $411 billion a year — about 2.28% of GDP — and roughly 1.2 million working days.

    RAND Europe (opens in a new tab)
  2. Erland & Saxena report in the Journal of Clinical Sleep Medicine that commercial melatonin content ranges from 83% below to 478% above the labelled dose, with serotonin found in some products.

    Journal of Clinical Sleep Medicine (opens in a new tab)
  3. Baron and colleagues coin "orthosomnia" in the Journal of Clinical Sleep Medicine, describing patients whose tracker-driven pursuit of perfect sleep made their sleep worse.

    Journal of Clinical Sleep Medicine (opens in a new tab)
  4. The American Academy of Sleep Medicine's clinical practice guideline makes CBT-I the strong, first-line recommendation for chronic insomnia and notes that sleep hygiene on its own is not an effective standalone treatment.

    American Academy of Sleep Medicine (opens in a new tab)
  5. A JMIR mHealth and uHealth multicenter study compares 11 consumer sleep trackers against polysomnography; sleep-stage agreement runs from poor to moderate across devices.

    JMIR mHealth and uHealth (opens in a new tab)
  6. A cross-sectional study of 523 adults in Brain Sciences puts estimated orthosomnia prevalence between about 3% and 14%, depending on the criteria applied.

    Brain Sciences (opens in a new tab)
  7. The Sleep Foundation notes that consumer sleep trackers are not regulated by the FDA as medical devices, and that one cited study found trackers correctly identified deep sleep around 59% of the time.

    Sleep Foundation (opens in a new tab)
  8. Hotels account for roughly 46% of the sleep-tourism market, with analysts projecting low-double-digit annual growth through 2030.

    Grand View Research (opens in a new tab)
  9. The National Sleep Foundation's Sleep in America poll finds six in ten US adults do not get the recommended seven to nine hours of quality sleep, and nearly four in ten struggle to fall asleep three or more nights a week.

    National Sleep Foundation (opens in a new tab)
  10. The Global Wellness Institute values the wellness economy at $6.8 trillion for 2024 and reports the sleep sub-segment of mental wellness growing about 12.6% a year from 2019 to 2024.

    Global Wellness Institute (opens in a new tab)
  11. Sleep tourism is named one of the year's defining travel trends, with hotels and resorts selling blackout suites, circadian lighting and "sleep concierges".

    Grand View Research (opens in a new tab)
  12. Forecast: the wellness economy reaches $9.8 trillion, per the Global Wellness Institute's projection.

    Global Wellness Institute (opens in a new tab)

Analysis

The cost is large, but it is a model — not an invoice

The commercial case for sleep rests on RAND Europe's 2016 estimate: up to $411 billion a year in the US, about 2.28% of GDP, and roughly 1.2 million working days lost. The direction is hard to argue with, but the figures are modelled ceilings from a 2016 study, and reading them as measured costs is the first mistake the category invites.

There is no single "sleep market" number

The Global Wellness Institute values the whole wellness economy at $6.8 trillion for 2024 and reports the sleep sub-segment of mental wellness growing about 12.6% a year from 2019 to 2024 — but it publishes no standalone sleep market size. Anyone quoting one clean figure is stitching sources together, which is why estimates for adjacent categories, such as a global mattress market somewhere between $49 billion and $58 billion, disagree by billions.

The strongest treatment is the one nobody can ship

For chronic insomnia the American Academy of Sleep Medicine's guideline makes CBT-I a strong, first-line recommendation, while stating that sleep hygiene on its own is not an effective standalone treatment. The best-evidenced intervention is therefore a structured therapy — not a mattress, a gadget or a supplement.

The label is a claim, not a guarantee

Erland & Saxena analyzed commercial melatonin products and found actual content between 83% below and 478% above the labelled dose; more than 70% of products missed their own label by more than 10%, and some contained serotonin as a contaminant. Light regulation is the reason the number on the bottle behaves like marketing copy.

Tracker error has a direction

Because consumer devices infer sleep largely from movement and heart rate, they tend to read lying still as being asleep — overestimating sleep for precisely the people most worried about it, such as insomniacs who lie awake without moving. The failure mode is not random noise; it flatters the user who needs accuracy most.

Prevalence numbers are a signal, not a verdict

The 523-adult Brain Sciences survey put orthosomnia prevalence anywhere from about 3% to 14% depending on how strictly it was defined, with roughly 36% of respondents using a tracker regularly. The sample skewed young and heavily female, so the range describes the state of measurement more than the state of the population.

Comparison

Estimate versus measurement: the wrist score and the sleep lab
DimensionConsumer wearable (estimate)Polysomnography (measurement)
How sleep is determinedInferred mostly from movement and heart rate, with the rest modelledBrain waves, eye movement, muscle activity, breathing and heart rhythm recorded overnight
Sleep-stage performanceFour-stage macro F1 of 0.26–0.69 across 11 devices, poor to moderateSleep stages scored directly; the clinical gold standard
Characteristic errorMistakes lying still for being asleep, overestimating sleep in insomniacsStages scored from recorded signals rather than inferred from motion
Stage detection accuracyOne cited study found deep sleep correctly identified around 59% of the timeUsed as the reference against which trackers are validated
Regulatory statusNot regulated by the FDA as a medical deviceA clinical study conducted in a sleep lab
What the output isA nightly score — a modelled estimate, not a diagnosisClinical data used for diagnosis
Evidence tiers behind the sleep economy's numbers
Claim or figureEvidence tierHow this article treats it
CBT-I for chronic insomniaStrong, first-line recommendation in the AASM clinical practice guideline (2021)The best-evidenced treatment
Sleep hygiene on its ownNot an effective standalone treatment per the same guidelineUseful habits, but not a substitute for treatment
MelatoninCan help circadian problems such as jet lag; long-term safety data beyond a few months is limitedNot a sedative; evidence thinner than the shelf space suggests
Market sizes (mattresses $49–58bn, sleep tourism, sleep tech)Commercial market-research estimates that vary by definitionQuoted as estimates only, with the spread named
RAND's up-to-$411bn annual cost2016 modelled estimate, not a measured costUsed for direction, not as a measured invoice
A nightly sleep scoreModelled output of movement and heart-rate dataAn estimate, kept in a separate column from diagnosis

Process

  1. Ask which tier the claim belongs to

    A clinical practice guideline, a peer-reviewed study and a market-research projection are not the same kind of statement.

  2. Find out who produced the number

    Most market sizes come from commercial research firms whose totals swing by billions depending on how each defines the category.

  3. Separate the estimate from the measurement

    A wrist score is inferred from movement and heart rate; polysomnography records brain waves, breathing and heart rhythm directly.

  4. Treat the label as a claim

    Commercial melatonin content ranged from 83% below to 478% above the labelled dose, and more than 70% of products missed their own label by over 10%.

  5. Start with the best-evidenced intervention

    For chronic insomnia that is CBT-I, a strong first-line recommendation — sleep hygiene alone is not an effective standalone treatment.

  6. Check whether the number has started running you

    When the pursuit of a better score becomes its own cause of insomnia, the product is working against its own promise — the pattern researchers named orthosomnia.

Sources

  1. RAND Europe — Why Sleep Matters: The Economic Costs of Insufficient Sleep (2016).View source (opens in a new tab)
  2. Global Wellness Institute — The Global Wellness Economy Hits a Record $6.8 Trillion, Forecast to Reach $9.8 Trillion by 2029 (2025-11-19).View source (opens in a new tab)
  3. National Sleep Foundation — 2025 Sleep in America Poll (2025-03).View source (opens in a new tab)
  4. American Academy of Sleep Medicine — Behavioral and Psychological Treatments for Chronic Insomnia Disorder: Clinical Practice Guideline (2021).View source (opens in a new tab)
  5. Journal of Clinical Sleep Medicine (Erland & Saxena) — Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content (2017-02-15).View source (opens in a new tab)
  6. JMIR mHealth and uHealth — Accuracy of 11 Wearable, Nearable, and Airable Consumer Sleep Trackers: Prospective Multicenter Validation Study (2023).View source (opens in a new tab)
  7. Journal of Clinical Sleep Medicine (Baron et al.) — Orthosomnia: Are Some Patients Taking the Quantified Self Too Far? (2017).View source (opens in a new tab)
  8. Brain Sciences (Jahrami et al.) — Prevalence of Orthosomnia in a General Population Sample: A Cross-Sectional Study (2024).View source (opens in a new tab)
  9. Sleep Foundation — What Is Orthosomnia? / Sleep Tracker Accuracy (2024).View source (opens in a new tab)
  10. Grand View Research — Sleep Tourism Market Size Report, 2025–2030 (2025).View source (opens in a new tab)

Tags

  • #sleep-economy
  • #sleep-tourism
  • #sleep-tracker
  • #sleep-hygiene
  • #orthosomnia
  • #wellness-economy